EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment

Yung-Tsung Kao iD, Chih-Ching Yen iD, Hueng-Chuen Fan iD, Jen-Kun Chen iD, Ming-Shan Chen, Ying-Wei Lan, Shang-Hsun Yang iD, Chuan-Mu Chen iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242216411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Yung-Tsung Kao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics, Mesenchymal Stem Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of Taiwan, Ministry of Education in Taiwan, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemophilia is a genetic disorder linked to the sex chromosomes, resulting in impaired blood clotting due to insufficient intrinsic coagulation factors. There are approximately one million individuals worldwide with hemophilia, with hemophilia A being the most prevalent form. The current treatment for hemophilia A involves the administration of clotting factor VIII (FVIII) through regular and costly injections, which only provide temporary relief and pose inconveniences to patients. In utero transplantation (IUT) is an innovative method for addressing genetic disorders, taking advantage of the underdeveloped immune system of the fetus. This allows mesenchymal stromal cells to play a role in fetal development and potentially correct genetic abnormalities. The objective of this study was to assess the potential recovery of coagulation disorders in FVIII knockout hemophilia A mice through the administration of human amniotic fluid mesenchymal stromal cells (hAFMSCs) via IUT at the D14.5 fetal stage. The findings revealed that the transplanted human cells exhibited fusion with the recipient liver, with a ratio of approximately one human cell per 10,000 mouse cells and produced human FVIII protein in the livers of IUT-treated mice. Hemophilia A pups born to IUT recipients demonstrated substantial improvement in their coagulation issues from birth throughout the growth period of up to 12 weeks of age. Moreover, FVIII activity reached its peak at 6 weeks of age, while the levels of FVIII inhibitors remained relatively low during the 12-week testing period in mice with hemophilia. In conclusion, the results indicated that prenatal intrahepatic therapy using hAFMSCs has the potential to improve clotting issues in FVIII knockout mice, suggesting it as a potential clinical treatment for individuals with hemophilia A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemostaticsMesenchymal Stem CellsPregnancyFemaleHumansMiceAnimalsInfantAmniotic FluidFactor VIIIMice, Knockout

Stichwörter der Autor:innen

FVIII inhibitorsamniotic fluid-mesenchymal stromal cellsclotting factor VIII (FVIII)hemophilia A mousein utero transplantation (IUT)stem cell therapy

Substanzen

Factor VIIIHemostatics

Autor:innen und Institutionen

  • Department of Life Sciences, Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.
  • Ph.D. Program in Tissue Engineering and Regenerative Medicine, National Health Research Institutes and National Chung Hsing University, Taichung 402, Taiwan.
  • Department of Internal Medicine, Pulmonary Medicine Section, China Medical University Hospital, and China Medical University, Taichung 404, Taiwan.
  • Department of Pediatrics, Department of Medical Research, Tungs' Taichung Metroharbor Hospital, Wuchi, Taichung 435, Taiwan.
  • Department of Rehabilitation, Jen-Teh Junior College of Medicine, Miaoli 356, Taiwan.
  • Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli 350, Taiwan.

ORCID-Profile: Yung-Tsung Kao, Chih-Ching Yen, Hueng-Chuen Fan, Jen-Kun Chen, Shang-Hsun Yang, Chuan-Mu Chen

Förderung

  • Ministry of Science and Technology of Taiwan
  • Ministry of Education in Taiwan
  • Ministry of Education

Zitieren

APA

Kao, Y. T., Yen, C. C., Fan, H. C., Chen, J. K., Chen, M. S., Lan, Y. W., Yang, S. H., & Chen, C. M. (2023). In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216411

Vancouver

Kao YT, Yen CC, Fan HC, Chen JK, Chen MS, Lan YW, et al. In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216411

BibTeX
@article{Kao2023,
  author = {Kao, Yung-Tsung and Yen, Chih-Ching and Fan, Hueng-Chuen and Chen, Jen-Kun and Chen, Ming-Shan and Lan, Ying-Wei and Yang, Shang-Hsun and Chen, Chuan-Mu},
  title = {In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242216411}
}
Kostenlos starten →